ES2181234T3 - Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica. - Google Patents

Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica.

Info

Publication number
ES2181234T3
ES2181234T3 ES98928391T ES98928391T ES2181234T3 ES 2181234 T3 ES2181234 T3 ES 2181234T3 ES 98928391 T ES98928391 T ES 98928391T ES 98928391 T ES98928391 T ES 98928391T ES 2181234 T3 ES2181234 T3 ES 2181234T3
Authority
ES
Spain
Prior art keywords
disorganizes
nucleic acid
extracellular matrix
gene therapy
associates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928391T
Other languages
English (en)
Inventor
Serge Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Association Francaise Contre les Myopathies
Original Assignee
Transgene SA
Association Francaise Contre les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Association Francaise Contre les Myopathies filed Critical Transgene SA
Application granted granted Critical
Publication of ES2181234T3 publication Critical patent/ES2181234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un producto de combinación que comprende al menos una sustancia que conlleva una desorganización de la matriz extracelular de una célula y al menos un ácido nucleico de interés, para una administración simultánea, consecutiva o extendida en el tiempo, siendo dicho ácido nucleico llevado por una partícula viral infecciosa o en forma de un vector sintético. LA invención se refiere también a su utilización con fines terapéuticos o de vacunación para la preparación de un medicamento destinado al tratamiento del cuerpo humano o animal por terapia génica así como a la utilización de una sustancia que conlleva una desorganización de la matriz extracelular para mejorar la transferencia y/o la expresión del ácido nucleico de interés arriba mencionado en una célula o un organismo huésped.
ES98928391T 1997-05-29 1998-05-29 Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica. Expired - Lifetime ES2181234T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9706600A FR2763958A1 (fr) 1997-05-29 1997-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique

Publications (1)

Publication Number Publication Date
ES2181234T3 true ES2181234T3 (es) 2003-02-16

Family

ID=9507375

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928391T Expired - Lifetime ES2181234T3 (es) 1997-05-29 1998-05-29 Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica.

Country Status (12)

Country Link
US (1) US6258791B1 (es)
EP (1) EP0980263B1 (es)
JP (1) JP2002500662A (es)
AT (1) ATE224736T1 (es)
AU (1) AU752146B2 (es)
CA (1) CA2291590A1 (es)
DE (1) DE69808274T2 (es)
DK (1) DK0980263T3 (es)
ES (1) ES2181234T3 (es)
FR (1) FR2763958A1 (es)
PT (1) PT980263E (es)
WO (1) WO1998053853A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU2038900A (en) * 1998-12-04 2000-06-26 Genzyme Corporation Methods for increasing the efficiency of gene transfer
WO2000038732A1 (de) * 1998-12-23 2000-07-06 Esparma Gmbh Hyaluronatlyase als penetrationsforderer in topischen mitteln
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20050004055A1 (en) * 2001-11-26 2005-01-06 Elena Fattori Increasing electro-gene transfer of nucleic acid molecules into host tissue
EP1480656A4 (en) * 2002-02-15 2007-07-18 Res Dev Foundation ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID
DE10211457A1 (de) * 2002-03-12 2003-09-25 Knoell Hans Forschung Ev Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
US7767429B2 (en) * 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US7888201B2 (en) * 2003-11-04 2011-02-15 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
JP2010519211A (ja) * 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
CA3061950A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
EP3833398A4 (en) 2018-09-21 2021-12-22 University of Connecticut COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
US12564646B2 (en) * 2021-06-16 2026-03-03 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5616483A (en) * 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer

Also Published As

Publication number Publication date
FR2763958A1 (fr) 1998-12-04
DK0980263T3 (da) 2003-02-03
CA2291590A1 (fr) 1998-12-03
US6258791B1 (en) 2001-07-10
AU8023898A (en) 1998-12-30
EP0980263B1 (fr) 2002-09-25
DE69808274T2 (de) 2003-05-15
WO1998053853A1 (fr) 1998-12-03
EP0980263A1 (fr) 2000-02-23
AU752146B2 (en) 2002-09-05
ATE224736T1 (de) 2002-10-15
PT980263E (pt) 2003-02-28
JP2002500662A (ja) 2002-01-08
DE69808274D1 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
PT980263E (pt) Produto de combinacao que associa um acido nucleico a uma substancia desorganizadora da matriz extracelular para terapia genetica
BR0010220A (pt) Compostos de pirimidinona
MX9602561A (es) Composicion que contiene acidos nucleicos, su preparacion y sus usos.
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
HN1999000083A (es) Compuestos de pirrolo(2,3-d) pirimidina
ES2196502T3 (es) Composicion y metodo para inhibir el desarrollo de microorganismos que incluye hipobromito sodico estabilizado e isotiazolonas.
TR200001603T2 (tr) Yeni bileşikler
TR200000197T2 (tr) Yeni bileşimler
BR0210593A (pt) polinucleotìdeos de defensina e métodos de uso
ID18145A (id) Asam fosfinik amida sebagai inhibitor metaloprotease matriks
AU2002359522A1 (en) Compositions and methods of selective nucleic acid isolation
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
ES2160892T3 (es) Uso de una mezcla de tensioactivos para inhibir la corrosion.
BR9801736A (pt) Processo de produção de dextrano.
PL342045A1 (en) 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases
AR018786A1 (es) Procedimiento de utilizacion que emplea un alquilpoliglicosido en formulaciones pesticidas como inhibidor del desarrollo de cristales y metodo para incrementar la eficacia biologica de composiciones pesticidas
FI970103A7 (fi) Mikro-organismeja sisältävä raekoostumus, menetelmä sen valmistamiseks i ja sen käyttö
AR010565A1 (es) Moleculas de acido nucleico aislados, proteina aislada, formulaciones que las contienen, composicion terapeutica, uso de un compuesto protector y uninhibidor para preparar una composicion terapeutica, metodo para producir una proteina de carboxilesterosa, metodo para identificar compuestos, equipo d
AU3042497A (en) Vaccine containing a peroxiredoxin and/or a beta-tubulin
BG100248A (bg) Инхибитори на скваленсинтетаза
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
ID17326A (id) Turunan-turunan asam 4-arilbutirat tersubstitusi sebagai inhibitor-inhibitor matriks metalloprotease
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent